Rita Valenzuela

发表

AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability

J. Lanciego, A. Rodriguez-Perez, J. Labandeira-Garcia, 2022, Brain, Behavior, and Immunity.

Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease

A. Rodriguez-Perez, J. Labandeira-Garcia, M. A. Pedrosa, 2022, npj Parkinson's Disease.

Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19

A. Rodriguez-Perez, J. Labandeira-Garcia, M. A. Pedrosa, 2021, Journal of Autoimmunity.

ANGIOTENSIN TYPE-1 RECEPTOR AND ACE2 AUTOANTIBODIES IN PARKINSON´S DISEASE

J. Labandeira-Garcia, C. Labandeira, P. Garrido-Gil, 2023, IBRO Neuroscience Reports.

Interactions between ibuprofen, ACE2, renin‐angiotensin system, and spike protein in the lung. Implications for COVID‐19

R. Franco, A. Rodriguez-Perez, J. Labandeira-Garcia, 2021, Clinical and translational medicine.

Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19

R. Franco, Gemma Navarro, A. Rodriguez-Perez, 2021, Clinical science.

The intracellular renin-angiotensin system: Friend or foe. Some light from the dopaminergic neurons

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2020, Progress in Neurobiology.

The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system

J. Labandeira-Garcia, R. Valenzuela, M. Meléndez‐Ferro, 2017, Cell Death & Disease.

Dopamine‐Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2013, Movement disorders : official journal of the Movement Disorder Society.

Interactions between Angiotensin Type-1 Antagonists, Statins, and ROCK Inhibitors in a Rat Model of L-DOPA-Induced Dyskinesia

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2023, Antioxidants.

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2012, Neurobiology of Aging.

Menopause and Parkinson’s disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2016, Frontiers in Neuroendocrinology.

R. Moratalla, J. Labandeira-Garcia, R. Valenzuela, 2014, Neurobiology of Aging.

Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin–angiotensin system in the nigra

J. Lanciego, J. Labandeira-Garcia, R. Valenzuela, 2012, Brain Structure and Function.

Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease.

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2012, American journal of neurodegenerative disease.

Review Article Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2012 .

Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra

R. Franco, Gemma Navarro, A. Rodriguez-Perez, 2019, Brain, Behavior, and Immunity.

Extracellular Vesicles and Their Renin–Angiotensin Cargo as a Link between Metabolic Syndrome and Parkinson’s Disease

A. Rodriguez-Perez, J. Labandeira-Garcia, C. Labandeira, 2023, Antioxidants.

J. Lanciego, R. Franco, Gemma Navarro, 2021, Redox biology.

Brain renin-angiotensin system and dopaminergic cell vulnerability

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2014, Front. Neuroanat..

Location of Prorenin Receptors in Primate Substantia Nigra: Effects on Dopaminergic Cell Death

J. Lanciego, P. Barroso-Chinea, J. Labandeira-Garcia, 2010, Journal of neuropathology and experimental neurology.

Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration

J. Lanciego, R. Franco, D. Henrion, 2016, Cell Death and Disease.

Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease

J. Lanciego, A. Rodriguez-Perez, J. Labandeira-Garcia, 2010, Experimental Neurology.

Drugs Modulating Renin-Angiotensin System in COVID-19 Treatment

A. Rodriguez-Perez, J. Labandeira-Garcia, M. A. Pedrosa, 2022, Biomedicines.

Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.

F. J. Luque, Modesto Orozco, F Javier Luque, 2005, Journal of medicinal chemistry.

Critical period for dopaminergic neuroprotection by hormonal replacement in menopausal rats

J. Lanciego, A. Rodriguez-Perez, J. Labandeira-Garcia, 2015, Neurobiology of Aging.

Dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats: role of the brain angiotensin system.

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2012, Brain : a journal of neurology.

Dual binding site acetylcholinesterase inhibitors

Ana Martínez, M. Medina, R. Valenzuela, 2007, Journal of Molecular Neuroscience.

Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson’s disease

Ovidiu Constantin Baltatu, J. Labandeira-Garcia, R. Valenzuela, 2010, The European journal of neuroscience.

Renin angiotensin system and gender differences in dopaminergic degeneration

A. Rodriguez-Perez, J. Labandeira-Garcia, R. Valenzuela, 2011, Molecular Neurodegeneration.

Ionizable nanoemulsions for RNA delivery into the central nervous system - Importance of diffusivity.

A. Rodriguez-Perez, Aloia Quijano, Rita Valenzuela, 2024, Journal of controlled release : official journal of the Controlled Release Society.